Latest Biotechnology Sector News

Page 6 of 6
Memphasys Limited has completed a pivotal Phase III trial confirming its Felix™ System as best-in-class for sperm separation, while advancing regulatory and commercial efforts in China and Brazil supported by fresh capital.
Ada Torres
Ada Torres
30 Apr 2025
Hexima Limited reported a stable cash position of $1.55 million at quarter-end, with a modest $87,000 net cash outflow from operations. The biotech company continues to explore strategic opportunities while maintaining a strong funding runway.
Ada Torres
Ada Torres
30 Apr 2025
Avecho Biotechnology has responded to an ASX price query, confirming no undisclosed information exists to explain recent trading spikes, while highlighting market speculation linked to its Phase III CBD insomnia trial.
Ada Torres
Ada Torres
14 Feb 2025
Recce Pharmaceuticals has temporarily paused trading of its securities, signaling a potentially significant development pending further disclosure.
Victor Sage
Victor Sage
13 Feb 2025
CSL Limited posted a robust half-year performance with NPATA rising 5% at constant currency, driven by strong growth in CSL Behring and CSL Vifor despite challenges in its influenza vaccine segment. The company reaffirmed its FY25 guidance, anticipating double-digit earnings growth.
Ada Torres
Ada Torres
11 Feb 2025
Biotron Limited reported a robust net cash inflow of $1.095 million for the December 2024 quarter, driven largely by government grants, supporting its operational stability despite ongoing R&D expenses.
Ada Torres
Ada Torres
3 Feb 2025
Medlab Clinical reports a near-empty cash balance and zero receipts in Q2 2025, while actively pursuing a business acquisition ahead of its ASX removal date.
Ada Torres
Ada Torres
3 Feb 2025
Neurotech International has secured a $2.44 million R&D tax incentive refund, strengthening its cash position as it advances clinical trials for paediatric neurological disorders and prepares for regulatory submissions in FY2025.
Ada Torres
Ada Torres
31 Jan 2025